Quantcast
Last updated on April 23, 2014 at 20:10 EDT

Latest Methylphenidate Stories

2011-01-05 13:54:43

Brain scans of children with attention-deficit/hyperactivity disorder (ADHD) have shown for the first time why people affected by the condition sometimes have such difficulty in concentrating. The study, funded by the Wellcome Trust, may explain why parents often say that their child can maintain concentration when they are doing something that interests them, but struggles with boring tasks. Using a 'Whac-a-Mole' style game, researchers from the Motivation, Inhibition and Development in ADHD...

2010-12-06 07:00:00

BURLINGTON, Mass., Dec. 6, 2010 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the attention-deficit/hyperactivity disorder (ADHD) drug market in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan will fluctuate modestly over the next decade, decreasing from $5 billion in 2009 to a trough in 2013 before climbing to $4.1 billion in 2019. An expanding drug-treated...

b8121ac3be407dd2051ab06df0f61fad1
2010-11-29 11:58:31

Adolescents and young adults are most likely to abuse prescription medications. Yet prescription rates for controlled medications, or drugs the Drug Enforcement Administration deems as having the potential for abuse, have nearly doubled for those age groups in the past 14 years, according to a recent study published in Pediatrics. Overall, a controlled medication was prescribed for young adults at approximately one out of every six visits and for young adult by adolescents one out of every...

2010-11-04 06:45:00

PISGAH FOREST, N.C., Nov. 4, 2010 /PRNewswire/ -- Pisgah Labs, Inc. (http://www.pisgahlabs.com), an innovative drug development and active ingredient manufacturer located in Western North Carolina, has received a substantial federal grant. The Qualifying Therapeutic Discovery Project Program (http://www.grants.nih.gov/grants/funding/QTDP_PIM/index.htm) made funding available to promising new technologies ready for pre-clinical or clinical trials, and to support filing of a New Drug...

2010-11-02 07:05:00

TITUSVILLE, N.J., Nov. 2, 2010 /PRNewswire/ -- Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI) today announced it has entered into a supply and distribution agreement with Watson Laboratories, Inc. to distribute an authorized generic version of CONCERTA® (methylphenidate HCl extended-release tablets). Watson will launch the authorized generic beginning May 1, 2011. "The availability of an authorized generic version of CONCERTA that is both bioequivalent and clinically...

2010-10-29 14:01:00

NEW YORK, Oct. 29 /PRNewswire/ -- Data presented today at a major medical meeting include findings that demonstrate improved handwriting performance in children with Attention Deficit Hyperactivity Disorder (ADHD) when taking CONCERTA® (OROS® methylphenidate HCl Extended-Release Tablets CII) compared to placebo. This data, which was presented by McNeil Pediatrics(TM), Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., is one of two sub-analyses...

2010-09-20 22:04:03

Hyperkinetic disorders among children and adolescents are becoming increasingly common. In the current issue of Deutsches Óžrzteblatt International, Ingrid Schubert of the PMV Research Group at the University of Cologne and her colleagues address the question how this has affected the frequency of prescriptions for methylphenidate, a stimulant drug that is used to treat such disorders (Dtsch Arztebl Int 2010; 107[36]: 615Â21). The authors analyzed data...

2010-09-14 12:35:16

Trial led by St. Jude Children's Research Hospital investigators finds medication restores sustained attention of many young survivors; work begins on new strategies to help survivors cope with this common challenge A medicine widely used to treat attention-deficit/hyperactivity disorder (ADHD) also provides long-term relief from the attention and behavior changes that affect many childhood cancer survivors, according to a multicenter trial led by St. Jude Children's Research Hospital...

ad7ac592f99bb46d52ca501e6447f8d91
2010-08-18 08:35:00

Nearly 1 million children in the United States are potentially misdiagnosed with attention deficit hyperactivity disorder simply because they are the youngest "“ and most immature "“ in their kindergarten class, according to new research by a Michigan State University economist. These children are significantly more likely than their older classmates to be prescribed behavior-modifying stimulants such as Ritalin, said Todd Elder, whose study will appear in a forthcoming issue of...

2010-08-10 14:50:00

DUBLIN, August 10, 2010 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced the divestiture of Daytrana(R) (methylphenidate transdermal system) to Noven Pharmaceuticals, Inc. Daytrana, which is approved and marketed in the US for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents, will continue to be available for patients through Noven. Shire's divestiture agreement grants...